\contentsline {section}{\tocsection {}{}{Foreword}}{i}{section*.1}%
\contentsline {section}{\tocsection {}{}{Abstract}}{ii}{section*.2}%
\contentsline {section}{\tocsection {}{1}{Introduction}}{1}{section.4}%
\contentsline {subsection}{\tocsubsection {}{1.1}{Alzheimerâ€™s Disease}}{1}{subsection.5}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.1.1}{Amyloid cascade hypothesis}}{1}{subsubsection.6}%
\contentsline {subsection}{\tocsubsection {}{1.2}{Human apolipoprotein-E gene}}{1}{subsection.7}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.2.1}{ApoE4 and Alzheimer's Disease}}{1}{subsubsection.8}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.2.2}{ApoE and ancestry in Alzheimer's Disease}}{1}{subsubsection.10}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.2.3}{ApoE and sex synergy in Alzheimer's Disease}}{2}{subsubsection.11}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.2.4}{Evolution of ApoE over time}}{2}{subsubsection.12}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.2.5}{Tissue expression}}{2}{subsubsection.13}%
\contentsline {subsection}{\tocsubsection {}{1.3}{Apo-lipoprotein E}}{3}{subsection.14}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.3.1}{Structure and function}}{3}{subsubsection.15}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.3.2}{ApoE isoforms}}{3}{subsubsection.17}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.3.3}{Lipidation nuances of ApoE isoforms}}{3}{subsubsection.18}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.3.4}{Interplay between ApoE lipidation and Alzheimer's Disease}}{3}{subsubsection.20}%
\contentsline {subsection}{\tocsubsection {}{1.4}{ApoE4-mediated metabolic changes in Alzheimer's Disease}}{4}{subsection.21}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.4.1}{Measured in \textit {post-mortem} brain tissue}}{5}{subsubsection.22}%
\contentsline {subsubsection}{\tocsubsubsection {}{1.4.2}{Measured in blood}}{5}{subsubsection.23}%
\contentsline {subsection}{\tocsubsection {}{1.5}{Research Questions}}{6}{subsection.25}%
\contentsline {section}{\tocsection {}{2}{Data}}{7}{section.29}%
\contentsline {section}{\tocsection {}{3}{Methodology}}{8}{section.30}%
\contentsline {subsection}{\tocsubsection {}{3.1}{Data management}}{8}{subsection.31}%
\contentsline {subsection}{\tocsubsection {}{3.2}{Data exploration and Visualisation}}{8}{subsection.32}%
\contentsline {subsection}{\tocsubsection {}{3.3}{Data Wrangling and Feature Engineering}}{8}{subsection.33}%
\contentsline {subsection}{\tocsubsection {}{3.4}{Statistical Analysis}}{8}{subsection.34}%
\contentsline {subsubsection}{\tocsubsubsection {}{3.4.1}{ApoE4 dose effects on serum metabolite levels in AD}}{8}{subsubsection.35}%
\contentsline {paragraph}{\tocparagraph {}{}{Global testing}}{8}{section*.38}%
\contentsline {subsubsection}{\tocsubsubsection {}{3.4.2}{Multi-class Classification of ApoE4 status and/or AD}}{9}{subsubsection.39}%
\contentsline {subsubsection}{\tocsubsubsection {}{3.4.3}{Metabolite Covariance Network analysis}}{10}{subsubsection.40}%
\contentsline {section}{\tocsection {}{4}{Results}}{11}{section.41}%
\contentsline {subsection}{\tocsubsection {}{4.1}{Data Exploration and Visualisation}}{11}{subsection.42}%
\contentsline {subsubsection}{\tocsubsubsection {}{4.1.1}{AD group}}{11}{subsubsection.44}%
\contentsline {subsubsection}{\tocsubsubsection {}{4.1.2}{SCD and AD}}{11}{subsubsection.47}%
\contentsline {subsection}{\tocsubsection {}{4.2}{RQi - Differential expression of plasma metabolites per ApoE4 dose among AD and SCD}}{11}{subsection.49}%
\contentsline {subsubsection}{\tocsubsubsection {}{4.2.1}{Global Test}}{11}{figure.52}%
\contentsline {subsubsection}{\tocsubsubsection {}{4.2.2}{ANOVA on Nested Linear Models}}{11}{subsubsection.53}%
\contentsline {subsection}{\tocsubsection {}{4.3}{RQii - Classification of metabolites on ApoE4 presence and AD}}{11}{figure.55}%
\contentsline {subsubsection}{\tocsubsubsection {}{4.3.1}{Adding 230 metabolites}}{12}{figure.57}%
\contentsline {subsubsection}{\tocsubsubsection {}{4.3.2}{Fitting the 6-factor Latent Projection of the 230 metabolites}}{12}{figure.59}%
\contentsline {subsection}{\tocsubsection {}{4.4}{RQiii - Covariance Network analysis of metabolites}}{12}{subsection.60}%
\contentsline {section}{\tocsection {}{5}{Discussion}}{16}{section.61}%
\contentsline {section}{\tocsection {}{6}{Conclusion}}{17}{section.62}%
\contentsline {section}{\tocsection {}{}{References}}{18}{section*.63}%
\contentsline {section}{\tocsection {Appendix}{A}{Multiclass ROC curves}}{23}{appendix.64}%
\contentsline {section}{\tocsection {Appendix}{B}{R Session Information}}{24}{appendix.67}%
\contentsline {section}{\tocsection {Appendix}{C}{R packages}}{25}{appendix.68}%
